MedTrace Logo

Vibe First In Human Study for the Assessment of Safety and Initial Performance of the Vibe Delivery System in Subjects With Idiopathic Overactive Bladder

NCT03874780 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2019-12-05

No results posted yet for this study

Summary

This First In Human study is aimed to evaluate the safety and initial efficacy of the Vibe delivery system in delivering Botox (TM) to the bladder wall in patients diagnosed with overactive bladder.

Conditions

Interventions

DEVICE

Vibe Delivery system

delivery of Botox (TM) to the bladder wall using an ultrasound technology with the Vibe delivery system

Sponsors & Collaborators

  • Vensica Therapeutics Ltd.

    lead INDUSTRY

Principal Investigators

  • ‪Maya Shick‬ · Consultant

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-29
Primary Completion
2019-03-31
Completion
2019-03-31

Countries

  • Czechia
  • Portugal

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03874780 on ClinicalTrials.gov